BackSumitomo Pharma , Ltd. Overview

Sumitomo Pharma , Ltd. Receivables

Latest receivables for SMDPY: $150B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$152.29B
↑ 17.79% YoYΔ $23.00B vs prior year quarter

Peer trimmed avg / median

Loading

Sumitomo Pharma , Ltd. Receivables History

Loading

Sumitomo Pharma , Ltd. vs. peers: Receivables Comparison

Loading

Sumitomo Pharma , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sumitomo Pharma , Ltd. (SMDPY) FAQ

Sumitomo Pharma , Ltd.'s receivables stands at $150B as of September 2026. That compares with $130B in the prior-year period — up 17.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sumitomo Pharma , Ltd. reported $150B in receivables versus $130B a year earlier — a 17.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $130B in the prior-year period — up 17.8% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sumitomo Pharma , Ltd.'s receivables evolved across reporting periods, while the comparison chart places SMDPY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.